Le Lézard
Classified in: Health, Science and technology
Subject: PERSONNEL ANNOUNCEMENTS

Cytovance(R) Biologics announces Michael O'Mara as Senior Vice President of Manufacturing Operations


OKLAHOMA CITY, OK--(Marketwired - January 17, 2017) - Cytovance® Biologics, Inc., a leading full service biopharmaceutical contract manufacture of mammalian and microbial biologics, today announced the addition of Mike O'Mara as Sr. Vice President of Manufacturing Operations.

"As Cytovance continues to grow, an efficient and collaborative manufacturing operation becomes critical to our clients' success," said Cytovance CEO Darren Head. "Mike brings to his new role a strong track record of success leading teams across our business, including mammalian, microbial operations and cell therapy manufacturing. He is the right leader to help shape our vision as we continue to grow and will be a great addition to our senior leadership team."

"I am honored to be recognized by Darren Head, President and CEO of Cytovance," said Mike O'Mara, "I have the benefit of working with an incredibly talented organization with standout performers at every level. I look forward to working with our executive team, the operations leadership team, the quality unit, and our gifted employees as we continue into the next phase of the company's evolution. Combining all of the 'execution' facets of the Cytovance organization under one umbrella will improve performance, reduce silo effects, and ultimately provide a better customer experience."

Mike O'Mara has more than 23 years' experience in biopharmaceutical contract manufacturing encompassing microbial, mammalian, and cell therapy manufacturing processes ranging from Preclinical/Phase I through Commercial. Prior to Cytovance, Mike worked at DynPort Vaccine Corporation as Senior Director of Manufacturing for 2 years. Mike was TissueGene's Vice President of Manufacturing, and worked for Lonza Biologics for 18 years in several operations and manufacturing positions. Mike has been part of numerous technology transfers, operational excellence initiatives, FDA and Regulatory agency audits, growing organizations and manufacturing expansions/build-outs. Mike holds a B.S in Microbiology from The University of Maryland.

About Cytovance Biologics

Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.


These press releases may also interest you

at 15:32
A report from GDToday:  On the evening of May 3, 2024, the Guangzhou Opera House dazzled audiences with the performance of "Marco Polo," a captivating opera commissioned by the esteemed venue. In order to commemorate the 700th anniversary of the...

at 13:20
Garrett Smith, Founder and CEO of Community Capital Technology Inc. ("Community Capital"), will be attending the Milken Institute Global Conference ("MI Global") May 5-8, 2024 in Los Angeles. The event brings together global executives and...

at 13:16
Quarterhill Inc. ("Quarterhill" or the "Company") , a leading provider of tolling and enforcement solutions in the Intelligent Transportation System ("ITS")...

at 12:25
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first and largest real-world patient cohort review...

at 09:05
Smart Meter, the leading supplier of Cellular Remote Patient Monitoring (RPM)tm solutions, has introduced a new version of the iGlucose, its patented cellular-connected glucose meter used by over 200,000 people with diabetes since 2019. The...

at 09:05
F5 announced that it has been singled out as a visionary in API security for its F5 Distributed Cloud Web App and API Protection (WAAP) in Enterprise Management Associates' Vendor Vision 2024 report. The report highlights "must see" security...



News published on and distributed by: